A Biomimetic Microfluidic Platform for Anti-tumor Drug Evaluation

Lara Reid, Wentao Shi, Yaling Liu Lehigh University Department of Bioengineering

Introduction

- Chemotherapy drugs are vital for treating and eliminating cancer in patients. Developing new and effective cancer drugs is difficult, because in vitro preclinical testing of drug candidates often yields inaccurate results which suggest the drug is more effective than it actually is. Thus, a drug evaluation platform that accurately mimics an in vivo tumor environment is imperative to the development of new anti-tumor drugs.
- Traditional 2D cell monolayer drug screening models do not accurately mimic an in vivo drug delivery environment. This presents a crucial limitation for accurately estimating the efficacy of a tumor drug in the human body.
- 3D models using tumor cell spheroids more accurately mimic the complex in vivo microenvironment in which a tumor is found.
- Here, microfluidic devices are designed to be biomimetic of a blood vessel by coating the device channel with endothelial cells.
- Paclitaxel, a chemotherapy drug, is administered through this "blood vessel" and interacts with tumor spheroids in the device.
- This allows for a drug evaluation model that accurately mimics drug transportation in an in vivo blood vessel environment.

Methods

 Microfluidic devices were constructed from glass and PDMS. A schematic of the microfluidic device is shown in Figure 1.




Figure 1: Schematic of the microfluidic device

- Endothelial cells (EC) were seeded into the apical channel to coat the semi-permeable membrane with an endothelial layer.
- HCT-116 tumor spheroids were seeded into the device's basal channel in a 1:1 ratio of Matrigel and spheroid-EC media solution, and was cured. A schematic of this is shown in Figure 2.




Figure 2: EC-loaded devices mimic the in vivo tumor environment

- different concentrations of Paclitaxel-doped media administered daily for 3 days to 8 devices' apical channels:
 - 0M (control), 1nM, 3 nM, 10nM, 30nM, 100nM, 300nM, 1µM

Results

Optical Coherence Tomography images of spheroids in the ECdevices generated 3D images¹ of the spheroids in the channel which were used for volume calculation. A 3D image is displayed in Figure 3.




Figure 3: OCT scans (left) and generated 3D image of a spheroid (right)

Cell staining using a dead/live cell staining kit and confocal microscopy showed higher cell viability in the well plate and EC-free device after 3-day drug treatment. This is displayed in Figure 4.





Figure 4: Dead-live staining for well plate and EC/EC-free devices (100nM)

Spheroid volume and cell viability decreased as drug treatment progressed, and the decrease was more rapid for higher drug concentrations. This is shown in Figure 5.



Discussion and Conclusions

- This biomimetic, 3D microfluidic drug screening platform better mimics the in vivo blood vessel microenvironment.
- The EC layer and Matrigel acted as hindrances to drug delivery, dramatically inhibiting drug delivery from the apical channel to the tumor spheroids.
- This research serves as an initial step toward anti-tumor drug evaluation in the form of a "lab-on-a-chip" platform.
- Further steps include a more complex microfluidic system which more closely mimics a blood vessel environment, automation, and testing other chemotherapy drugs with the device.

References

Y. Huang, S. Wang, Q. Guo, S. Kessel, I. Rubinoff, L.L.-Y. Chan, P. Li, Y. Liu, J. Qiu, and C. Zhou, Cancer Res. 77, 6011 (2017).

Acknowledgement(s):

David and Lorraine Freed Undergraduate Research Symposium, Lehigh University

The authors acknowledge the support of this work from the Pennsylvania Infrastructure Technology Alliance (PITA), National Science Foundation (NSF) Grant Nos. NSF IIP 1611718, and National Institutes of Health (NIH) Grant Nos. R01HL131750.

